Janus Living Inc. Class A-1 Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.79B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Janus Living Inc. Class A-1 Common Stock is far larger — about 4.7× uniQure N.V. Ordinary Shares's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.97% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| JAN | QURE | |
|---|---|---|
Market Cap | $6.79B | $1.45B |
Volume | 1,802,875 | 3,323,243 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $70.59 |
52-Week Low | $22.88 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.88B | $707.46M |
Dividend Yield | 1.97% | — |
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →